CLINICAL IMMUNOLOGY
Functional activity of natural killer cells in biological fluids in patients with colorectal and ovarian cancers
Submission date: 2016-10-26
Final revision date: 2017-04-04
Acceptance date: 2017-04-05
Publication date: 2018-03-30
Cent Eur J Immunol 2018;43(1):26-32
KEYWORDS
ABSTRACT
Aim of the study:
To compare the functional activity of natural killer cells depending on the presence of a malignant process and its dissemination.
Material and methods:
The study included 20 patients with Stage IIIB, C (FIGO, 2009) ovarian cancer, 10 patients with benign ovarian tumours (BOT), and 20 patients with colorectal cancer (T2-4N0-2M0). The control group consisted of 9 healthy donors. To evaluate the number and functional activity of NK cells, multicolour flow cytometry was performed.
Results:
In cancer patients, the relative number of activated NK cells secreting granzyme B (GB) (CD56+CD107a+GB+PF–) was significantly decreased, and the proportion of degranulated NK cells (CD56+CD107a+GB–PF–) was significantly increased, compared to those observed in healthy donors. The total number of NK cells in peripheral blood was low in ovarian cancer patients (p < 0.05). The proportion of activated peripheral blood NK cells containing cytolytic granules GB and perforin (PF) in colorectal cancer patients increased with tumour growth. However, lymph node metastasis did not affect the content and activation of NK cells. Comparative analysis of NK-cell populations in patients with benign and malignant ovarian tumours revealed that the level of CD56+ cells was significantly higher in ascites than in peripheral blood. However, CD56+CD107a+ activated cells and CD56+CD107a+GB+PF+ cells were found more frequently in ascites of BOT patients than in ovarian cancer patients. The degranulated population of NK cells (CD56+CD107a+GB–PF–) was mainly observed in the peripheral blood of ovarian cancer patients.
To compare the functional activity of natural killer cells depending on the presence of a malignant process and its dissemination.
Material and methods:
The study included 20 patients with Stage IIIB, C (FIGO, 2009) ovarian cancer, 10 patients with benign ovarian tumours (BOT), and 20 patients with colorectal cancer (T2-4N0-2M0). The control group consisted of 9 healthy donors. To evaluate the number and functional activity of NK cells, multicolour flow cytometry was performed.
Results:
In cancer patients, the relative number of activated NK cells secreting granzyme B (GB) (CD56+CD107a+GB+PF–) was significantly decreased, and the proportion of degranulated NK cells (CD56+CD107a+GB–PF–) was significantly increased, compared to those observed in healthy donors. The total number of NK cells in peripheral blood was low in ovarian cancer patients (p < 0.05). The proportion of activated peripheral blood NK cells containing cytolytic granules GB and perforin (PF) in colorectal cancer patients increased with tumour growth. However, lymph node metastasis did not affect the content and activation of NK cells. Comparative analysis of NK-cell populations in patients with benign and malignant ovarian tumours revealed that the level of CD56+ cells was significantly higher in ascites than in peripheral blood. However, CD56+CD107a+ activated cells and CD56+CD107a+GB+PF+ cells were found more frequently in ascites of BOT patients than in ovarian cancer patients. The degranulated population of NK cells (CD56+CD107a+GB–PF–) was mainly observed in the peripheral blood of ovarian cancer patients.
REFERENCES (20)
1.
Baginska J, Viry E, Paggetti J, et al. (2013): The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol 4: 490.
2.
Larsen SK, Gao Y, Basse PH (2014): NK cells in the tumor microenvironment. Crit Rev Oncog 19: 91-105.
3.
Apetoh L, Obeid M, Tesniere A, et al. (2007): Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. Cancer Genomics Proteomics 4: 65-70.
4.
Hannani D, Sistigu A, Kepp O, et al. (2011): Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 17: 351-358.
5.
Stakheeva MN, Kzhyshkowska YG, Buldakov MA, et al. (2015): Mechanisms of immune system contribution to efficiency of antitumor cytostatic therapy. Vopr Onkol 61: 546-55.
6.
Cohnen A, Chiang SC, Stojanovic A, et al. (2013): Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood 122: 1411-1418.
7.
Krzewski K, Gil-Krzewska A, Nguyen V, et al. (2013): LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity. Blood 121: 4672-4683.
8.
Bamias A, Tsiatas ML, Kafantari E, et al. (2007): Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol 106: 75-81.
9.
Verhaak RG, Tamayo P, Yang JY, et al. (2013): Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123: 517-525.
10.
Bryceson YT, Fauriat C, Nunes JM, et al. (2010): Functional analysis of human NK Cells by flow cytometry. Methods Mol Biol 612: 335-352.
11.
Cornfield DB, Gheith SM (2009): Flow cytometric quantitation of natural killer cells and T lymphocytes expressing T-cell receptors alpha/beta and gamma/delta is not helpful in distinguishing benign from malignant body cavity effusions. Cytometry B Clin Cytom 76: 213-217.
12.
Lukesova S, Vroblova V, Tosner J, et al. (2015): Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp Oncol (Pozn) 19: 290-299.
13.
Bai D, Yang G, Yuan H, et al. (1999): Perioperative cimetidine application modulates natural killer cells in patients with colorectal cancer: a randomized clinical study. J Tongji Med Univ 19: 300-303.
14.
Peng YP, Zhu Y, Zhang JJ, et al. (2013): Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patient with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med 11: 262.
15.
Kim JC, Choi J, Lee SJ, et al. (2013): Evaluation of cytolytic activity and phenotypic changes of circulating blood immune cells in patients with colorectal cancer by a simple preparation of peripheral blood mononuclear cells. J Korean Surg Soc 85: 230-235.
16.
Carlsten M, Björkström NK, Norell H, et al. (2007): DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 67: 1317-1325.
17.
Rocca YS, Roberti MP, Arriaga JM (2013): Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun 19: 76-85.
18.
Abakushina EV (2015): The technique of flow cytometry in evaluation of NK-cells and their activity. Klin Lab Diagn 60: 37-44.
19.
Bamias A, Koutsoukou V, Terpos E, et al. (2008): Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNF alpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 108: 421-427.
20.
Fossati M, Buzzonetti A, Monego G, et al. (2015): Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3). Gynecol Oncol 138: 343-351.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
